JP2002519425A - 神経変性疾患および癌の処置に有用な新規なインドロカルバゾール誘導体 - Google Patents

神経変性疾患および癌の処置に有用な新規なインドロカルバゾール誘導体

Info

Publication number
JP2002519425A
JP2002519425A JP2000558102A JP2000558102A JP2002519425A JP 2002519425 A JP2002519425 A JP 2002519425A JP 2000558102 A JP2000558102 A JP 2000558102A JP 2000558102 A JP2000558102 A JP 2000558102A JP 2002519425 A JP2002519425 A JP 2002519425A
Authority
JP
Japan
Prior art keywords
tau
halide
carbons
conr
substance
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000558102A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002519425A5 (enExample
Inventor
ロダー，ハンノ
ロウインガー，テイモシー・ビー
ブリテリ，デイビツド・アール
バンザント，マイケル・シー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer AG
Original Assignee
Bayer AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer AG filed Critical Bayer AG
Publication of JP2002519425A publication Critical patent/JP2002519425A/ja
Publication of JP2002519425A5 publication Critical patent/JP2002519425A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/16—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2000558102A 1998-07-02 1999-06-23 神経変性疾患および癌の処置に有用な新規なインドロカルバゾール誘導体 Pending JP2002519425A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/109,131 1998-07-02
US09/109,131 US6013646A (en) 1998-07-02 1998-07-02 Indolocarbazole derivatives useful for the treatment of neurodegenerative diseases and cancer
PCT/EP1999/004369 WO2000001699A1 (en) 1998-07-02 1999-06-23 Novel indolocarbazole derivatives useful for the treatment of neurodegenerative diseases and cancer

Publications (2)

Publication Number Publication Date
JP2002519425A true JP2002519425A (ja) 2002-07-02
JP2002519425A5 JP2002519425A5 (enExample) 2006-08-10

Family

ID=22325955

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000558102A Pending JP2002519425A (ja) 1998-07-02 1999-06-23 神経変性疾患および癌の処置に有用な新規なインドロカルバゾール誘導体

Country Status (6)

Country Link
US (2) US6013646A (enExample)
EP (1) EP1091962A1 (enExample)
JP (1) JP2002519425A (enExample)
AU (1) AU754399B2 (enExample)
CA (1) CA2336419A1 (enExample)
WO (1) WO2000001699A1 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6013646A (en) 1998-07-02 2000-01-11 Bayer Corporation Indolocarbazole derivatives useful for the treatment of neurodegenerative diseases and cancer
US6660750B2 (en) 2000-02-15 2003-12-09 University Of Iowa Research Foundation Flavopiridol methods and compositions for HIV therapy
US20030181473A1 (en) * 2000-02-29 2003-09-25 Palmer Peter Albert Farnesyl protein transferase inhibitor combinations with taxane compounds
AU2001261324A1 (en) * 2000-05-08 2001-11-20 Psoriasis Research Institute Psoriasis treatment
US7129250B2 (en) * 2000-05-19 2006-10-31 Aegera Therapeutics Inc. Neuroprotective and anti-proliferative compounds
CA2308994A1 (en) * 2000-05-19 2001-11-19 Aegera Therapeutics Inc. Neuroprotective compounds
DE60229437D1 (de) * 2001-12-13 2008-11-27 Pharmacyclics Inc Verfahren zur beeinflussung neurologischer progression
DE10161940A1 (de) * 2001-12-17 2003-07-03 Nad Ag N-Carbacyclus-monosubstitutierte Indolocarbazole als Proteinkinase-inhibitoren
WO2003078448A1 (en) * 2002-03-13 2003-09-25 Signum Biosciences, Inc. Modulation of protein methylation and phosphoprotein phosphate
DE10255343B4 (de) * 2002-11-27 2006-09-07 Nad Ag N,N-Verbrückte, Stickstoff-Substituierte Carbacyclische Indolocarbazole als Proteinkinase-Inhibitoren
US20110008327A1 (en) 2004-03-29 2011-01-13 Cheng Jin Q Compositions including triciribine and epidermal growth factor receptor inhibitor compounds or salts thereof and methods of use thereof
US20100173864A1 (en) 2004-03-29 2010-07-08 Cheng Jin Q Compositions including triciribine and one or more platinum compounds and methods of use thereof
US20100028339A1 (en) 2004-03-29 2010-02-04 Cheng Jin Q Compositions including triciribine and trastuzumab and methods of use thereof
CN1984663A (zh) 2004-03-29 2007-06-20 南佛罗里达大学 用曲西瑞宾和相关化合物有效治疗肿瘤和癌症
US20100009929A1 (en) 2004-03-29 2010-01-14 Cheng Jin Q Compositions including triciribine and bortezomib and derivatives thereof and methods of use thereof
US20100009928A1 (en) 2004-03-29 2010-01-14 Cheng Jin Q Compositions including triciribine and taxanes and methods of use thereof
DE102004025726B4 (de) 2004-05-26 2006-07-06 Roder, Hanno, Dr. Verwendung eines spezifischen K252a-Derivats zur Verhinderung oder Behandlung der Alzheimerschen Krankheit
US20060058250A1 (en) * 2004-09-10 2006-03-16 Cephalon, Inc. Methods of treating proliferative skin diseases using carbazole derivatives
WO2006084033A1 (en) * 2005-02-03 2006-08-10 Signum Biosciences, Inc. Compositions and methods for enhancing cognitive function
US7923041B2 (en) 2005-02-03 2011-04-12 Signum Biosciences, Inc. Compositions and methods for enhancing cognitive function
EP1876900A4 (en) * 2005-05-02 2009-06-24 Univ Columbia PHOSPHOINOSITIDE MODULATION FOR THE TREATMENT OF ALZHEIMER DISEASE
US20070249590A1 (en) * 2005-10-28 2007-10-25 Wilson Lawrence J Substituted indolo[2,3-a]pyrrolo[3,4-c]carbazole compounds useful in treating kinase disorders
CN1870631B (zh) * 2005-11-11 2010-04-14 华为技术有限公司 媒体网关的门控方法
EP2124554B1 (en) * 2006-12-14 2012-02-08 Tautatis, Inc. Compositions and methods for the treatment of cancer
US20100273769A1 (en) * 2009-01-26 2010-10-28 Hanno Roder Composition and method for the treatment of parkinson's disease

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04187686A (ja) * 1990-11-20 1992-07-06 Meiji Seika Kaisha Ltd インドロカルバゾール誘導体

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4968690A (en) * 1986-05-27 1990-11-06 United States Government As Represented By The Secretary Of The Dept. Of Health And Human Services 3-deazaneplanocin, intermediates for it, and antiviral composition and method of treatment using it
WO1988007045A1 (fr) * 1987-03-09 1988-09-22 Kyowa Hakko Kogyo Co., Ltd. Derives de la substance physiologiquement active k-252
JPH07113027B2 (ja) * 1987-12-24 1995-12-06 協和醗酵工業株式会社 Ｋ−２５２誘導体
US5618809A (en) * 1989-12-14 1997-04-08 Schering Corporation Indolocarbazoles from saccharothrix aerocolonigenes copiosa subsp. nov SCC 1951 ATCC 53856
US5189046A (en) * 1990-08-14 1993-02-23 Nova Pharmaceutical Corporation Protein kinase C modulators
US5955444A (en) 1991-08-09 1999-09-21 Massachusetts Institute Of Technology Method of inhibiting abnormal tau hyper phosphorylation in a cell
DE69232121T2 (de) * 1991-08-09 2002-06-20 Massachusetts Institute Of Technology, Cambridge Verwendungen einer proteinkinase von ton und neurofilament pk40
NZ245203A (en) * 1991-11-29 1997-07-27 Banyu Pharma Co Ltd 5h-indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7(6h)-dione derivatives substituted in position-13 by a pentose or hexose group; corresponding indolo-furano(anhydride)intermediates
US5607691A (en) * 1992-06-12 1997-03-04 Affymax Technologies N.V. Compositions and methods for enhanced drug delivery
EP0575955B1 (en) * 1992-06-22 1999-09-15 Kyowa Hakko Kogyo Co., Ltd. Process for producing staurosporine derivatives
US5621101A (en) * 1992-07-24 1997-04-15 Cephalon, Inc. Protein kinase inhibitors for treatment of neurological disorders
US5461146A (en) * 1992-07-24 1995-10-24 Cephalon, Inc. Selected protein kinase inhibitors for the treatment of neurological disorders
JPH08500112A (ja) * 1992-08-12 1996-01-09 ジ・アップジョン・カンパニー タキソールと組み合わせるプロテインキナーゼ阻害剤および関連化合物
WO1994020106A1 (fr) * 1993-03-03 1994-09-15 Kyowa Hakko Kogyo Co., Ltd. Renforceur de sensibilite pour agent antineoplasique
WO1994027982A1 (en) * 1993-05-28 1994-12-08 Cephalon, Inc. Use of indolocarbazole derivatives to treat a pathological condition of the prostate
US5468872A (en) * 1993-09-16 1995-11-21 Cephalon, Inc. K-252a functional derivatives potentiate neurotrophin-3 for the treatment of neurological disorders
US5624949A (en) * 1993-12-07 1997-04-29 Eli Lilly And Company Protein kinase C inhibitors
EP1449529B1 (en) * 1993-12-23 2010-01-27 Eli Lilly And Company Protein Kinase C Inhibitors
US5654307A (en) * 1994-01-25 1997-08-05 Warner-Lambert Company Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family
WO1995022331A1 (en) * 1994-02-18 1995-08-24 Cephalon, Inc. Aqueous indolocarbazole solutions
US5491242A (en) * 1994-06-22 1996-02-13 Eli Lilly And Company Protein kinase C inhibitors
US5594009A (en) * 1994-10-14 1997-01-14 Cephalon, Inc. Fused pyrrolocarbazoles
US5648378A (en) * 1995-06-07 1997-07-15 Research Corporation Technologies, Inc. 2-iminochromene derivatives as inhibitors of protein tyrosine kinase
US6013646A (en) 1998-07-02 2000-01-11 Bayer Corporation Indolocarbazole derivatives useful for the treatment of neurodegenerative diseases and cancer

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04187686A (ja) * 1990-11-20 1992-07-06 Meiji Seika Kaisha Ltd インドロカルバゾール誘導体

Also Published As

Publication number Publication date
EP1091962A1 (en) 2001-04-18
WO2000001699A1 (en) 2000-01-13
AU4776699A (en) 2000-01-24
AU754399B2 (en) 2002-11-14
US6541468B1 (en) 2003-04-01
CA2336419A1 (en) 2000-01-13
US6013646A (en) 2000-01-11

Similar Documents

Publication Publication Date Title
US6541468B1 (en) Indolocarbazole derivatives useful for the treatment of neurodegenerative diseases and cancer
EP3864003B1 (en) Prodrug modulators of the integrated stress pathway
ES2973442T3 (es) Moduladores de la vía integrada del estrés
US11939320B2 (en) Modulators of the integrated stress pathway
TWI767915B (zh) Ror-1與btk拮抗劑的組合
US20240018133A1 (en) Modulators of the integrated stress pathway
US20240000792A1 (en) Modulators of the integrated stress pathway
JP2019500377A (ja) がん及び炎症性疾患の処置のための化合物
EP3807251B1 (en) Phenyl and pyridinyl substituted imidazoles as modulators of roryt
JP7858643B2 (ja) 統合的ストレス経路の調節剤
HK1215250A1 (zh) 氨基取代的异噻唑
CN114269343A (zh) 用于治疗癌症的方法和组合物
CN115697331A (zh) Taspase1抑制剂及其用途
EA029372B1 (ru) Пиразолопиримидиновые соединения
JP2006515275A (ja) ベンゾピラノン化合物、その組成物および癌の治療または予防方法
WO2008016661A2 (en) Morpholino compounds for treating inflammatory and demyelinating diseases and cancers
HK40060429A (en) Prodrug modulators of the integrated stress pathway
HK40060429B (en) Prodrug modulators of the integrated stress pathway
HK40012051B (en) Modulators of the integrated stress pathway
HK40012051A (en) Modulators of the integrated stress pathway
HK40010265A (en) Cancer treatment combinations

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060619

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060619

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20080328

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100427

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20101005